However, TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) in HFpEF [68, 69] and ALBATROSS trial (Aldosterone Lethal effects Blocked in Acute Myocardial Infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) in patients with acute myocardial infarction, 92% of whom presented without heart failure [70], both trials failed to support these findings about the effectiveness of MR antagonist in reducing cardiovascular mortality and heart failure hospitalizations (Table 1). This evidence concerns the gene NR3C2 and myocardial infarction.